BioLineRx Enters into $5.6 Million Royalty Monetization Transaction with Soleus Capital

On November 18, 2026 BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, reported that it has entered into an agreement for the sale of its rights to certain future royalty payments from APHEXDA (motixafortide) to Soleus Capital Management, L.P. and its affiliates ("Soleus") for a one-time payment of $5.6 million.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Under the terms of the agreement, Soleus will acquire BioLineRx’s 14.4% royalty interest in future net sales of APHEXDA under the Company’s existing license agreement with Ayrmid Pharma Ltd. ("Ayrmid"). The transaction excludes the remaining 3.6% royalty interest attributable to the original licensor of motixafortide to BioLineRx, which will continue to retain its interest in the royalty stream. BioLineRx has retained its rights to receive potential commercial milestone payments under the Ayrmid agreement, as well as royalty payments attributable to periods prior to the closing of the transaction.

"This transaction enables us to immediately unlock the value of our APHEXDA royalty stream and strengthen our financial position while retaining the potential for future commercial milestone payments," said Philip Serlin, Chief Executive Officer of BioLineRx. "Importantly, the non-dilutive capital will provide additional financial flexibility as we continue to advance our lead development asset, GLIX1, through its ongoing Phase 1/2a clinical trial in glioblastoma and other solid tumors. We believe this transaction represents an attractive, non-dilutive financing solution for our company and our shareholders."

"We are pleased to partner with BioLineRx on this transaction, which provides us with an opportunity to participate in the future commercial performance of APHEXDA," said Benjamin Lund, Partner at Soleus Capital. "We believe APHEXDA represents a differentiated treatment option in stem cell mobilization for patients with multiple myeloma, and we look forward to supporting BioLineRx through this innovative financing arrangement."

BioLineRx intends to use the proceeds to support its ongoing research and development activities, including the clinical development of GLIX1, as well as for working capital and general corporate purposes, including a partial loan repayment to BlackRock EMEA Venture and Growth Lending. In connection with the partial loan repayment, the Company’s minimum cash balance requirement under the loan agreement (currently $4 million) will be eliminated. The transaction is expected to close on or about November 30, 2026.

About APHEXDA (motixafortide)
APHEXDA is a CXCR4 antagonist approved by the U.S. Food and Drug Administration for use in combination with filgrastim (G-CSF) to mobilize hematopoietic stem cells to the peripheral blood for collection and subsequent autologous stem cell transplantation in patients with multiple myeloma. APHEXDA is being commercialized by Ayrmid globally, except in Asia, where it is partnered with Gloria Biosciences.

(Press release, BioLineRx, NOV 18, 2026, View Source [SID1234674918])